September 18, 2025 — Cambridge, Massachusetts Intellia has completed enrollment in the global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), an investigational CRISPR-based gene editing therapy for hereditary angioedema (HAE). Enrollment finished within nine months after dosing the first patient in January 2025, with nearly half of participants enrolled in the United States. Topline Phase 3 data are expected in the first half of 2026 and the sponsor plans a Biologics License Application (BLA) submission in late 2026.
Science Significance
The HAELO trial tests lonvo-z, a single-infusion, in vivo CRISPR/Cas9 therapy engineered to inactivate the KLKB1 gene, which encodes prekallikrein and drives kallikrein-mediated swelling in HAE. The randomized, double-blind, placebo-controlled study enrolls at least 60 adults and adolescents (16 years and older) randomized 2:1 to receive a single 50 mg infusion of lonvo-z or placebo, with an optional blinded crossover at week 28. Key endpoints include the number of HAE attacks and the number of patients who achieve attack-free status from week 5 through week 28, outcomes that directly measure clinical benefit and durability. Early Phase 1/2 data showed dramatic reductions in attack frequency and consistent, deep and durable decreases in kallikrein levels, supporting the biological rationale for KLKB1 inhibition and the potential for a durable, disease-modifying effect.
Regulatory Significance
Lonvo-z has received multiple expedited designations—Orphan Drug and RMAT (Regenerative Medicine Advanced Therapy) from the U.S. FDA, an Innovation Passport from the U.K. MHRA, and PRIME status from the European Medicines Agency—which enable prioritized regulatory engagement, potential accelerated review, and incentives such as fee waivers and market exclusivity if approved. These regulatory pathways facilitate detailed, early dialogue on pivotal endpoints, safety monitoring and post-approval evidence generation, and they materially improve the prospects for coordinated global filings and a more efficient route to patient access should Phase 3 confirm benefit.
Business Significance
Advertisement
Completing Phase 3 enrollment in under a year reflects strong operational execution, effective site activation and clear patient and investigator engagement. If Phase 3 confirms the safety and efficacy signals seen earlier, a one-time gene editing therapy would alter the HAE commercial model by replacing chronic prophylactic regimens, reducing lifetime treatment costs, and lowering emergency care utilization. That health-economic profile strengthens the value proposition to payers, supports the case for innovative reimbursement models (including outcome-based or annuity approaches), and could attract strategic collaborations to support manufacturing scale-up and global rollout.
Patients’ Significance
For people living with HAE, who face unpredictable, painful and sometimes life-threatening swelling attacks, lonvo-z offers the prospect of fewer attacks, fewer emergency interventions and relief from the logistical burden of frequent prophylactic dosing. Inclusion of adolescents in the trial broadens the potential patient impact across age groups. If durable kallikrein suppression translates into sustained clinical benefit, patients may experience improved daily functioning, reduced anxiety about attacks, fewer missed work or school days, and an overall better quality of life.
Policy Significance
The HAELO program underscores the role of targeted rare-disease policies and expedited regulatory pathways in enabling high-impact therapies to reach patients faster. Policymakers and payers will need to adapt reimbursement frameworks to reflect long-term value from one-time genetic interventions while ensuring equitable access across populations. Robust post-approval registries and real-world evidence collection will be essential to monitor long-term safety, durability and health-economic outcomes and to inform future coverage and payment strategies.
Completing enrollment in the Phase 3 HAELO trial is a pivotal milestone for in vivo gene editing and for the HAE community. With topline results expected in 2026 and a targeted BLA submission planned for late 2026, lonvo-z could become the first one-time, disease-modifying therapy for hereditary angioedema, setting a template for durable genetic interventions in other rare conditions; stakeholders will now watch closely for efficacy, safety and long-term durability as the program advances toward regulatory review and potential patient access.
Source: Intellia Therapeutics Press Release
